Rid­ing on rosy es­ti­mates of Zol­gens­ma sales, Re­genxBio sells part of its roy­al­ty for $200M

Re­genxBio’s jour­ney as a drug de­vel­op­er may have been less than rosy, but there’s been lit­tle doubt about the val­ue of the gene ther­a­py tech­nol­o­gy it ob­tained from Jim Wil­son’s labs.

Health­care Roy­al­ty Man­age­ment has made that clear once again, strik­ing a deal to buy a por­tion of its roy­al­ties on Zol­gens­ma for $200 mil­lion.

Ac­cord­ing to the lat­est quar­ter­ly fil­ing from Re­genxBio, it’s re­ceived $40.7 mil­lion in roy­al­ties in the first nine months of 2020, com­pared to just over $10 mil­lion in the same pe­ri­od in 2019.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER